HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Protective effect of Xuebijing injection on paraquat-induced pulmonary injury via down-regulating the expression of p38 MAPK in rats.

AbstractBACKGROUND:
Exposure to paraquat results in acute lung injury. A systemic inflammatory response has been widely established as a contributor to paraquat-induced acute lung injury. Recent studies have reported that consumption of Xuebijing prevents inflammatory response-induced diseases. This study investigated whether consumption of Xuebijing protected rats against paraquat-induced acute lung injury.
METHODS:
Adult male Sprague Dawley rats were randomly divided into four groups: control group; paraquat group; paraquat + Xuebijing group; and paraquat + dexamethasone group. Rats in the paraquat, paraquat + Xuebijing and paraquat + dexamethasone groups were intraperitoneally injected with paraquat (30 mg/kg) or administered paraquat and Xuebijing at 8 mL/kg or dexamethasone at 5 mg/kg, respectively, via an injection into the tail vein. Lung p38 MAPK, NF-κB65, IkB, p-IκB-α, HIF-1α, Nrf2 and TGF-β1 expression were essayed using western blotting. IL-6, TNF-α, IL-1β, IL-10, TGF-β1 and PIIIP were measured using ELISA. ROS, oxidised glutathione and glutathione activity were measured.
RESULTS:
After inducing acute lung injury with paraquat for 24 h, Xuebijing was observed to block lung p-p38 MAPK, NF-κB65, HIF-1α, p-IκB-α and TGF-β1 expression, and increased Nrf2 and IkB expression. The numbers of neutrophils and lymphocytes and total number of cells were significantly lower in the Xuebijing group compared with the control group. IL-6, TNF-α, IL-1β, TGF-β1 and PIIIP levels were significantly decreased in the Xuebijing group. ROS and oxidised glutathione activity were markedly inhibited by Xuebijing. Histological evaluation showed attenuation of the effects of Xuebijing on paraquat-induced lung injury. Compared with the paraquat + dexamethasone group, the Xuebijing + paraquat group showed no significant differences.
CONCLUSIONS:
Inhibiting the expression of p38 MAPK and NF-κB65 was crucial for the protective effects of Xuebijing on paraquat-induced acute lung injury. The findings suggest that Xuebijing could effectively ameliorate paraquat-induced acute lung injury in rats. Xuebijing was as effective as dexamethasone at improving paraquat-induced lung injury by regulating lung inflammation, lung function and oxidative stress responses.
AuthorsMing-wei Liu, Mei-xian Su, Wei Zhang, Yan-qiong Wang, Mei Chen, Li Wang, Chuan-yun Qian
JournalBMC complementary and alternative medicine (BMC Complement Altern Med) Vol. 14 Pg. 498 (Dec 16 2014) ISSN: 1472-6882 [Electronic] England
PMID25511395 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Inflammatory Agents
  • Antioxidants
  • Drugs, Chinese Herbal
  • Herbicides
  • I-kappa B Proteins
  • Interleukin-1beta
  • Interleukin-6
  • Nfkbia protein, rat
  • Transforming Growth Factor beta1
  • Tumor Necrosis Factor-alpha
  • Xuebijing
  • Interleukin-10
  • NF-KappaB Inhibitor alpha
  • p38 Mitogen-Activated Protein Kinases
  • Paraquat
Topics
  • Acute Lung Injury (drug therapy, metabolism)
  • Animals
  • Anti-Inflammatory Agents (pharmacology, therapeutic use)
  • Antioxidants (metabolism, pharmacology, therapeutic use)
  • Down-Regulation
  • Drugs, Chinese Herbal (pharmacology, therapeutic use)
  • Herbicides (adverse effects)
  • I-kappa B Proteins (metabolism)
  • Injections, Intraperitoneal
  • Interleukin-10 (metabolism)
  • Interleukin-1beta (metabolism)
  • Interleukin-6 (metabolism)
  • Lung (drug effects, metabolism, pathology)
  • Male
  • NF-KappaB Inhibitor alpha
  • Oxidative Stress (drug effects)
  • Paraquat (adverse effects)
  • Phytotherapy
  • Pneumonia (drug therapy, metabolism)
  • Pulmonary Edema (drug therapy, metabolism)
  • Rats
  • Rats, Sprague-Dawley
  • Transforming Growth Factor beta1 (metabolism)
  • Tumor Necrosis Factor-alpha (metabolism)
  • p38 Mitogen-Activated Protein Kinases (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: